FIELD: biotechnology.
SUBSTANCE: binding proteins, represented by immunoglobulins with double variable domains that bind IL-1α and IL-1β are claimed. In addition, the invention relates to methods for preparation, as well as application of these proteins, including as part of a pharmaceutical composition, for treatment of a disease or disorder in which the IL-1α and IL-1β or IL-1β activity is malicious.
EFFECT: invention allows IL-1α binding with IL-1β with high affinity .
32 cl, 2 dwg, 24 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
IL-1 BINDING PROTEINS | 2011 |
|
RU2615173C2 |
IMMUNOGLOBULIN WITH DOUBLE VARIABLE DOMAINS AND ITS APPLICATIONS | 2006 |
|
RU2515108C2 |
TREATING OSTEOARTHRITIS AND PAIN | 2012 |
|
RU2563830C2 |
ANTI-VEGF/DLL4-IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAINS AND THEIR APPLICATION | 2013 |
|
RU2636043C2 |
INTERLEUKIN-13-BINDING PROTEINS | 2012 |
|
RU2605327C2 |
INTERLEUKIN-13-BINDING PROTEINS | 2016 |
|
RU2650767C2 |
THERAPEUTIC DLL4-BINDING PROTEINS | 2011 |
|
RU2605928C2 |
NEW FORM OF IL33, MUTATED FORMS OF IL33, ANTIBODIES, ANALYZES AND METHODS OF USING THEM | 2016 |
|
RU2736299C2 |
INTERLEUKIN-13 BINDING PROTEINS | 2007 |
|
RU2472807C2 |
MONOCLONAL ANTIBODIES AGAINST PROTEIN RGM A AND APPLICATION THEREOF | 2009 |
|
RU2524136C2 |
Authors
Dates
2017-08-03—Published
2011-12-20—Filed